Induction of Donor-Specific Tolerance in Recipients of Live Donor Stem Cell Infusion (Compassionate Use)

NCT02051673 · Status: NO_LONGER_AVAILABLE · Type: EXPANDED_ACCESS

Last updated 2022-07-18

No results posted yet for this study

Summary

Four subjects were treated under compassionate use provisions under this study with facilitating cell therapy (FCRx)

Conditions

  • Renal Failure

Interventions

BIOLOGICAL

Biological/Vaccine: Enriched Hematopoetic Stem Cell Infusion

Enriched Hematopoetic Stem Cell Infusion

Sponsors & Collaborators

Principal Investigators

  • Suzanne T Ildstad, MD · Talaris Therapeutics Inc.

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Countries

  • United States

Study Locations

More Related Trials

Entities

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02051673 on ClinicalTrials.gov